CAMBRIDGE, Mass., December 21, 2018 – Axcella Health, a biotechnology company pioneering a new approach to address metabolic dysregulation and health, today announced that Svetlana Marukian, Ph.D., Senior Director, Discovery, will present new data from Axcella’s AXA1125 liver program at the Integrated Pathways of Disease in NASH and NAFLD Keystone Symposium, taking place January 20-24, 2019 in Santa Fe, NM. New data in primary human single and multicellular systems show that AXA1125, a novel AXA candidate, affects metabolic, inflammatory and fibrotic pathways. These results demonstrate high fidelity to observations in T2DM subjects with NAFLD recently presented at the 2018 American Association for the Study of Liver Diseases (AASLD) Liver Meeting®.

Additional details of the presentation are as follows:

Title: Unique Composition of Endogenous Modulators Impact Metabolic, Inflammation, and Fibrotic Markers in NAFLD/NASH Model Systems

Presenter: Svetlana Marukian, Ph.D., Senior Director of Discovery

Session: Innate Immune and Inflammatory Signaling

Location: Eldorado Grand Ballroom, Eldorado Hotel

Date/Time: Tuesday, January 22, 2019 at 5:00 PM MT

About Endogenous Metabolic Modulators

Endogenous metabolic modulators (EMMs), which include amino acids, regulate fundamental pathways in health and disease. Compositions leveraging EMMs hold significant promise, with several advantages over traditional drugs and food/dietary supplement products, including their ability to simultaneously impact multiple biological pathways and history of safe use.

About Non-IND Clinical Studies

Axcella conducts Non-IND, IRB-approved food studies to evaluate the safety and tolerability of its AXA candidates in human subjects, or effects on the normal structure or function of the body. Studies intended to directly support drug development will be conducted under an IND. Axcella has not determined the development path for AXA1125.

About Axcella™ Health

Axcella is designing and developing novel endogenous metabolic modulator compositions to safely reprogram metabolic dysregulation. We are transforming the discovery and development of traditional drug and consumer health candidates from concept to clinical stages, by leveraging our deep understanding of human biology. Our novel approach rapidly gains unprecedented information in a capital efficient manner. Our platform has already produced a rich pipeline of product candidates in programs targeting liver, muscle, and CNS. Axcella Health was founded by Flagship Pioneering.

# # #

Media Contact
Stefanie Tuck
MacDougall Biomedical Communications

Company Contact
Alison Williams

*The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Axcella disavows any obligation to update the information contained in such press releases after the date of their issuance.